Short answer
HARROW, INC. (HROW) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $99M (up 38.6% year over year) with net income of $10M.
Q3 2026 key financials · XBRL
- Revenue
- $99M
- +38.6% YoY · +40.5% QoQ
- Net income
- $10M
- +856.6% YoY · +156.5% QoQ
- Operating margin
- 11.6%
- Gross margin
- 75.4%
- EPS (diluted)
- $0.26
- +766.7% YoY · +156.5% QoQ
Source: XBRL data from the HARROW, INC. (HROW) Q3 2026 10-Q on SEC EDGAR. USD.
HARROW, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $99.297M, up $27.659M YoY from $71.638M
- Best performer VEVYE, revenue $39.699M, up $17.073M YoY
- Worst performer compounding, revenue $15.835M, down $4.221M YoY
- Branded gross margin 79.3% vs 81.6% YoY, compounding margin 55.2% vs 59.0%
- Cash $75.336M at September 30, operating cash flow nine-month use $27.363M; $48.915M financing inflow from 2030 Notes
- TYRVAYA expected to contribute over $30M revenue in 2027, with approximately $20M annual operating expenses; licensor discussions remain unresolved
Risk Factors
- New risk: TYRVAYA acquisition triggered potential VEVYE license conflict, requiring divestiture or rights termination
- Financial risk: Up to $70,000,000 in TYRVAYA contingent milestone payments may remain payable
- Regulatory risk: Proposed CMS GLOBE and GUARD models could increase ophthalmic-product rebates using international benchmarks
- Market risk: Payor step edits, prior authorization, and formulary restrictions could reduce reimbursed patient access
- Reporting risk: Inaccurate rebate and chargeback estimates could reduce revenues, margins, and cash flows
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other HARROW, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.